Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink

INTRODUCTION: This real-world safety analysis was requested by the European Medicines Agency following approval of apremilast, an oral treatment for psoriasis or psoriatic arthritis. OBJECTIVE: We aimed to compare incidence rates of adverse events of special interest identified a priori, in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Persson, Rebecca, Cordey, Myriam, Paris, Maria, Jick, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510500/
https://www.ncbi.nlm.nih.gov/pubmed/36151359
http://dx.doi.org/10.1007/s40264-022-01235-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510500/
https://www.ncbi.nlm.nih.gov/pubmed/36151359
http://dx.doi.org/10.1007/s40264-022-01235-7

Ejemplares similares